"Efficacy of tapered fidaxomicin dosing regimens to treat simulated Clostridium difficile infection (CDI) in an in vitro gut model", , 14 May 2014 (2014-05-14), XP055182784, Retrieved from the Internet: URL:http://www.researchgate.net/profile/Ch ris_Longshaw/publication/262292381_Efficac y_of_tapered_fidaxomicin_dosing_regimens_t o_treat_simulated_Clostridium_difficile_in fection_(CDI)_in_an_in_vitro_gut_model/lin ks/02e7e53737f70bb807000000.pdf?origin=pub lication_detail [retrieved on 2015-04-14] (B1)

C. Chilton ET AL: "2013: K-336. Comparison of Extended Duration Fidaxomicin Dosing Regimens for Treatment of Clostridium difficile Infection (CDI) in an in vitro Gut Model", , September 2013 (2013-09), XP055182841, Retrieved from the Internet: URL:http://www.icaaconline.com/php/icaac20 13abstracts/data/papers/2013/K/2013_K-336. htm [retrieved on 2015-04-14] cited in the application (B1)

C. H. CHILTON ET AL: "Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 14 June 2015 (2015-06-14), XP055205152, ISSN: 0305-7453, DOI: 10.1093/jac/dkv156 (B1)

C. H. CHILTON ET AL: "Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 69, no. 2, 3 September 2013 (2013-09-03), pages 451-462, XP055182651, ISSN: 0305-7453, DOI: 10.1093/jac/dkt347 cited in the application (B1)

G. W. TANNOCK ET AL: "A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin", MICROBIOLOGY, vol. 156, no. 11, 19 August 2010 (2010-08-19), pages 3354-3359, XP055182699, ISSN: 1350-0872, DOI: 10.1099/mic.0.042010-0 (B1)

M. M. SORIANO ET AL: "Novel Fidaxomicin Treatment Regimens for Patients With Multiple Clostridium difficile Infection Recurrences That Are Refractory to Standard Therapies", OPEN FORUM INFECTIOUS DISEASES, vol. 1, no. 2, 1 August 2014 (2014-08-01), pages ofu069-ofu069, XP055182559, DOI: 10.1093/ofid/ofu069 (B1)

WO-A2-2005/112990 (B1)

Soriano et al.: "Abstract: The use of a fidaxomicin chaser as effective salvage therapy for vancomycin-refractory, recurrent Clostridium difficile infections (IDWeek 2013)", , 5 October 2013 (2013-10-05), XP055182724, Retrieved from the Internet: URL:https://idsa.confex.com/idsa/2013/webp rogram/Paper42591.html [retrieved on 2015-04-14] cited in the application -& Melinda M Soriano ET AL: "The Use of a Fidaxomicin Taper/Pulsed Chaser as Effective Salvage Therapy for Vancomycin-Refractory, Recurrent Clostridium difficile Infections", , 5 October 2013 (2013-10-05), XP055182720, Retrieved from the Internet: URL:https://idsa.confex.com/idsa/2013/webp rogram/Paper42591.html [retrieved on 2015-04-14] (B1)

T. J. LOUIE ET AL: "Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI", CLINICAL INFECTIOUS DISEASES, vol. 55, no. suppl 2, 2 July 2012 (2012-07-02), pages S132-S142, XP055205254, ISSN: 1058-4838, DOI: 10.1093/cid/cis338 (B1)

Ther Adv: "Therapeutic Advances in Gastroenterology Review", , 2012, pages 395-402, XP055182638, Retrieved from the Internet: URL:http://www.ncbi.nlm.nih.gov/pmc/articl es/PMC3491684/pdf/10.1177_1756283X12461294 .pdf (B1)

WO-A1-2013/138748 (B1)

WO-A1-2014/111254 (B1)

S. JOHNSON ET AL: "Fidaxomicin "Chaser" Regimen Following Vancomycin for Patients With Multiple Clostridium difficile Recurrences", CLINICAL INFECTIOUS DISEASES, vol. 56, no. 2, 28 September 2012 (2012-09-28), pages 309-310, XP055182579, ISSN: 1058-4838, DOI: 10.1093/cid/cis833 (B1)